Tumor cells typically escape destruction of cytotoxic T lymphocyte (CTL) by upregulating immune checkpoint ligands such as PD-L1, which can depress lymphocyte activation by binding to complementary receptors (PD-1) on CTL (Klement et al., 2023; Yang et al., 2023). The gene discussed is PDCD1; the disease is neoplasm.